MedWatch

Denmark passes on four new medicines, recommends two

The Danish Medicines Council has gone over six submissions during its August meeting, four of which were scrapped.

Photo: Stine Rasmussen/Ritzau Scanpix

On Wednesday last week, the Danish Medicines Council had bad news for Abbvie, Genzyme, and AOP Orphan Pharmaceuticals Sweden.

During its monthly meeting, the council rejected an application from Abbvie, which was seeking support to use Skyrizi (risankizumab) in adult patients with active psoriatic arthritis who do not benefit from conventional disease modifying antirheumatic drugs.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs